Invesco IVZ

Financial Services · Asset Management · Synthos Deep Dive · 2026-07-03

$32.86

Buy — Tactical

—

The Overview

Invesco is a money-management firm. People and institutions hand it their savings — through mutual funds and ETFs like the famous QQQ (the Nasdaq-100 fund) — and Invesco charges a small yearly fee on the roughly $2.2 trillion it manages. Its income rises and falls with two things: how much money customers add or pull out, and whether the stock and bond markets go up or down.

Is the stock cheap or expensive? Roughly fairly priced, leaning slightly cheap. It trades around 9–10× next year's expected profit (asset managers usually trade about 10–13×), pays a ~3% dividend, and is buying back its own shares. The catch is that the whole industry keeps having to cut fees, so profits grind rather than sprint.

Our verdict is Watch — a decent, improving business at a fair price, but nothing forcing you to buy today.

Here's what our three scores mean in everyday terms:

Downside Risk 6/10 (a bit above average). The stock swings more than the market (high "beta"), and if markets fall its revenue falls with them. It carries real debt, though it also throws off a lot of cash.
Growth Quality 5/10 (middle of the road). It's finally growing again after years of customers leaving — a good sign — but only slowly.
Exponential Potential 3/10 (low). This is a big, mature company. It can grind higher and pay you to wait, but it is not going to double quickly.

The one big worry: Invesco doesn't control its own revenue. A market downturn shrinks the $2.2 trillion it manages, and fees keep drifting lower across the whole industry — so a bad year can hit profits hard with little management can do about it.

Putting a number on it: our fair-value estimate is $31 against a current price of $32.86 — a premium price for a business we still like.

Target entry zone $30 – $33 accumulate in this band; ideal adds on a dip toward the 50-day average near $30

Our summary metrics

Downside Risk (lower = safer)6/10High

High beta (1.59) & market-linked AUM; leverage optically high (net debt $8.1B + $2.5B preferred), but FCF yield ~15% cushions.

Growth Quality5/10Moderate

11 straight quarters of organic inflows & QQQ open-end conversion lifting fees, but ~6% forward EPS CAGR — steady, not fast.

Exponential Potential3/10Low

Mature $2.2T asset manager in a fee-compressing industry; scale is defensive, not a multibagger engine.

Fair value$31 $21–$39

What does “fair value” mean?

Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.

The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.

What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)

Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.

Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.

WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.

HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.

AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.

Exponential Potential

Exponential Potential3/10Low

Mature $2.2T asset manager in a fee-compressing industry; scale is defensive, not a multibagger engine.

What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.

Deeper analysis

Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.

Check our number Market-implied growth ≈ 10%/yr This isn’t how we calculate fair value — it’s public math you can verify yourself. To justify today’s $33, earnings would have to compound roughly 10% a year for 10 years (9% discount rate). Analysts forecast ~14%/yr, so the market is pricing in LESS than what the Street expects.

Reference table

Street consensus	$30.06 (high $34.50 / low $26.00; 12 Buy · 16 Hold · 0 Sell → Hold) — context, not our anchor
Valuation	Negative trailing GAAP EPS (impairment) · ~10× FY26E adj · ~9× FY27E adj · EV/EBITDA 16× · P/B ~1.0× · FCF yield ~15%
Technicals	Neutral-to-up — $27.01, −8% off 52-wk high, just below 50-DMA, above 200-DMA, RSI 40, +67% 12-mo (SPY +21%)
Conviction	None — zero net-bullish voices, zero traceable claims in the Synthos KB; call rests on fundamentals + quant
Position sizing	Satellite / value-income, ~1–3% if entered; a Watch until the flow story is proven durable

What the experts actually said

No independent expert claims in the Synthos knowledge base yet for IVZ — this dive is fundamentals- and technicals-driven, not panel-driven.

Price & moving averages 12 months · 50 & 200-day averages · 52-week range

Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.

Bollinger Bands 20-day average ± 2 standard deviations

The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.

RSI (14) momentum gauge · 0–100

Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 62.

MACD 12 / 26 / 9 · trend & momentum

The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.

Relative performance vs S&P 500 & its sector (XLF (sector)), set to 100 a year ago

Solid = IVZ · dashed = S&P 500 · dotted = XLF (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.

Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate

Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.

Key stats an RIA wants

Price$32.86

Market cap$15B

P/E trailingn/m (loss-making or n/a)

P/E FY26E / FY27E12× / 10×

EV / Salesn/a — vendor EV unreliable

EV / EBITDAn/a — vendor EV unreliable

Gross margin67.4%

Net margin-0.9%

Dividend yield2.59%

Beta1.596

52-wk range$22 – $33

RSI(14)61

50 / 200-DMA$30 / $27

12-mo return+49% (SPY +19%)

Street target$33 ($28–$39)

Analyst grades12 Buy · 16 Hold · 0 Sell

FMP ratingC+

Next earnings2026-07-28 (Q2'26 earnings; Street EPS est $0.61, revenue ~$1.26B)

EV multiples are withheld for this name: the vendor’s enterprise value differs from our own rebuild (market cap + total debt − cash − short-term investments) by more than 15%, so we do not know which is right. Rather than print a figure we cannot stand behind, we show none — the discussion in the body uses the corrected basis and says so.

1. What it is

Invesco Ltd. (NYSE: IVZ) is a global, independent asset manager headquartered in Atlanta, founded in 1935. It runs mutual funds, ETFs, unit trusts, closed-end funds and institutional/retirement mandates across equities, fixed income, multi-asset and private markets. At the end of Q1 2026 it managed ~$2.16 trillion in AUM (up 17% year-on-year). Its best-known asset is QQQ, the Invesco QQQ Trust tracking the Nasdaq-100 — which on December 20, 2025 was converted from a unit investment trust (UIT) to an open-end ETF, a structural change that lets Invesco earn management fees on it for the first time (a meaningful positive to fee revenue, visible in Q1'26). CEO: Andrew Schlossberg. Fiscal year ends December 31.

Revenue mix (FY2025, from FMP segmentation):

By type: Investment advice (management fees) $4.62B (72%) · Distribution & shareholder service $1.52B (24%) · Financial service/other $0.20B · Investment-performance fees $0.04B. This is a fee-on-AUM business: management fees dominate, so revenue tracks AUM levels.
By geography: Americas $4.77B (75%) · EMEA (ex-UK) $1.32B (21%) · Asia $0.30B (5%). Americas-concentrated, with a growing Asia-Pacific franchise (notably the China JV, a strong flow contributor in Q1'26).

The story management is selling is operating leverage on a re-accelerating flow base: 11 consecutive quarters of positive long-term organic growth, expense discipline, and scale benefits driving adjusted operating margin up ~300 bps year-on-year to 34.5% in Q1'26.

2. The expert thesis (no expert coverage)

There is no expert coverage of IVZ in the Synthos knowledge base. total_claims = 0; there are zero net-bullish (or net-bearish) voices and zero traceable claim_ids. Unlike our conviction-track names, this note carries no distilled expert panel behind it.

Accordingly, this verdict is fundamentals- and quant-driven only. Every judgment below is anchored to the reported financials (FMP), the analyst-estimate consensus (labeled as estimates), management's own earnings release (half-weighted, §9), and the technical/valuation picture — not to any expert conviction. We will not manufacture conviction we do not have: where the case is genuinely uncertain, we say so and land on Watch rather than pretend to a signal.

For external context only (not Synthos conviction): the sell-side is split — 12 Buy / 16 Hold / 0 Sell, a "Hold" consensus, with price targets $26–$34.50.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

Score	0–10	The read
Downside Risk (lower = safer)	6 · Moderate-High	Beta 1.59 and market-linked AUM make earnings cyclical; leverage looks high (net debt $8.1B + $2.5B preferred, EV/EBITDA 16×), though a ~15% FCF yield and P/B ~1.0× cushion the downside.
Growth Quality	5 · Moderate	11 straight quarters of organic inflows, QQQ fee capture and +300 bps margin expansion are real quality signals — but forward EPS CAGR is only ~6% and the industry compresses fees.
Exponential Potential	3 · Low	A mature $2.2T manager in a scale-and-cost game. Defensive moat, not an accelerant; the multibagger case isn't here.

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them. All EPS below are on an adjusted (non-GAAP) basis — FY25 GAAP was distorted by a $1.79B Q4 intangible impairment; the industry and the Street value these firms on adjusted EPS.

Case	Key assumptions	Fair value
Bull	Flows stay strongly positive, markets rise, QQQ + China JV + private markets compound AUM past $2.4T; adj EPS beats to ~$3.20 (FY27); the market pays a re-rated ~12× for a proven grower.	~$39 (+44%)
Base (our anchor)	Organic growth continues low-single-digit; markets flat-to-up; FY27E adj EPS ~$3.00; a fair ~10.5× asset-manager multiple.	~$31 (+15%)
Bear	A market drawdown shrinks AUM, flows stall, fee compression bites; adj EPS slips toward ~$2.30; multiple de-rates to ~9× as the turnaround narrative fades.	~$21 (−22%)

Synthos fair value = the base case, ~$31 (+15%), with the full $21–$39 span as the honest range. Our base sits essentially on top of the Street's $30.06 consensus — we don't see a large edge here, which is itself a reason for Watch rather than Buy. This is a tracked call — the Forecaster Scorecard grades it once it matures.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating multi-baggers-from-here). IVZ is neither a high-return compounder nor an exponential — it is a mature cyclical turning the corner:

Forward growth: on consensus estimates, revenue is roughly flat-to-modestly-up (adjusted net revenue $4.6B FY25 → ~$5.6B FY29E area) and adj EPS CAGR is ~6% (FY26E $2.63 → FY29E $3.61). Steady, not fast.
Acceleration (2nd derivative): genuinely positive off a low base — the flow trend inflected from years of outflows to 11 straight quarters of inflows, and QQQ's open-end conversion is a one-time step-up in captured fees. But this is a recovery to normalcy, not a new exponential S-curve; the estimate path decelerates after the QQQ bump.
Room to run: the addressable pool (global managed assets) is enormous, but IVZ is a fee-taker in a structurally fee-compressing, scale-dominated industry where the largest passive players (Vanguard, BlackRock, State Street) set the terms. Scale here is defensive — a cost moat — not a lever for a 5×.
Reinvestment runway: capital is being returned (dividend raised to $0.215/qtr, buybacks stepping up to $40M/qtr) and debt paid down, not plowed into a high-ROIC reinvestment flywheel. That's the right move for a mature firm — but it caps the exponential case.

Exponential Potential: Low (3/10). Own IVZ, if at all, for value + income + a self-help turnaround, not for multibagger torque. Honest framing: this is a satellite value name, not a Synthos flagship exponential.

5. Financials (real numbers — FMP annual/quarterly)

AUM: $2.16T at Q1'26 (+17% YoY); average AUM +18% YoY — the single most important driver, and it's rising.
Revenue (GAAP operating): FY25 $6.38B (+5.1% on FY24 $6.07B). Q1'26 operating revenue $1.74B, +14.1% YoY, helped by the QQQ conversion. On an adjusted net revenue basis (management's preferred, stripping pass-through distribution costs) Q1'26 was $1.26B, +14% YoY.
Margins: Q1'26 GAAP operating margin 19.1%; adjusted operating margin 34.5% (+300 bps YoY) — the operating-leverage story is real and showing up.
Earnings — read carefully: FY25 GAAP was a loss (bottom-line −$726M; EPS −$1.61) almost entirely due to a $1.79B non-cash impairment of indefinite-lived intangibles in Q4'25, not operating deterioration. Underlying quarters are solidly profitable: Q1'26 GAAP EPS $0.51, adjusted EPS $0.57 (+30% YoY). We anchor valuation on adjusted EPS for this reason.
Cash flow: FY25 operating cash flow $1.53B, capex only ~$84M, free cash flow ~$1.44B → a ~15% FCF yield on a $12B cap. This is the balance-sheet's saving grace and funds the dividend + buyback + de-levering.
Balance sheet: total debt $10.1B, net debt $8.1B; separately ~$2.5B of preferred stock (the MassMutual Series A) sits ahead of common. Reported net-debt/EBITDA TTM is optically 7.3×, but that EBITDA is depressed by the impairment; against ~$1.7B run-rate adjusted operating income the leverage is high-but-serviceable. IVZ redeemed $500M of senior notes at January 2026 maturity — de-levering is underway. P/B ~1.0×.

6. Valuation — priced in or room?

On trailing GAAP numbers IVZ screens as loss-making (the impairment), so trailing P/E is meaningless here. On the metrics that matter for an asset manager:

Forward P/E (adjusted): ~10× FY26E ($2.63) · ~9× FY27E ($3.04) — a discount to the typical 10–13× asset-manager range and to its own growth-plus-yield.
Yield & return of capital: ~3.1% dividend (raised to $0.215/qtr) plus a stepped-up buyback ($40M in Q1'26) — a mid-single-digit total shareholder yield before growth.
EV/EBITDA 16×, P/S 1.8×, P/B ~1.0×, FCF yield ~15%. The FCF yield is the standout: you're buying ~$1.4B of free cash flow for $12B.
Reverse read: at ~$27 the market is pricing IVZ roughly for continuation of low-single-digit growth with no multiple re-rating — i.e., the flow turnaround is treated as fragile. If the 11-quarter inflow streak proves durable and margins hold, a re-rate toward 12× on ~$3 gets you to the high-$30s.

Street targets (context): consensus $30.06, high $34.50, low $26.00. Our $31 base fair value is essentially in line — a ~15% total-return case including the dividend, not a deep-value fat pitch. Cheap enough to respect; not cheap enough to pound the table. Fairly-valued-with-optionality, hence Watch.

7. Technicals (from the tech block)

Trend: neutral-to-constructive. $27.01 sits just below the 50-DMA ($27.19) but comfortably above the 200-DMA ($25.52) — a mild consolidation within a longer uptrend. MACD slightly negative (−0.21).
Location: −8.3% off the 52-week high ($29.44), +62.8% off the 52-week low ($16.59) — well off the lows, moderate pullback from the highs (max drawdown from peak −8.3%).
Momentum: RSI(14) 40 — soft, neither overbought nor washed out; room to move either way.
Relative strength (the tell): IVZ +67.0% 12-mo vs SPY +20.6% and QQQ +30.3% — a big year of catch-up as the turnaround got recognized; but +2.1% 6-mo vs SPY +8.4% shows the easy re-rating has cooled and the stock is now digesting gains.
Read: technicals are neutral — the 12-month leadership confirms the turnaround was real, but the recent stall and sub-50-DMA price say there's no urgency. A hold of the 200-DMA (~$25.50) on any market wobble would be a lower-risk entry zone.

8. Moat & competitive position

Invesco's moat is scale and distribution breadth, not a proprietary product edge: ~$2.2T across a diversified vehicle set (ETFs, mutual funds, institutional, private markets) with the QQQ franchise as a genuine crown jewel and a growing China JV. In active asset management the structural tide runs against the industry — persistent fee compression and share loss to ultra-low-cost passive giants. IVZ's defenses are (1) QQQ, a top-tier ETF brand now earning management fees post-conversion; (2) global distribution including a differentiated Asia/China footprint; and (3) cost discipline delivering operating leverage. But it lacks the sheer scale of BlackRock or the cost position of Vanguard, so it competes as a strong second-tier diversified manager.

Peer set (from FMP, market cap): Franklin Resources (BEN) $17.7B and Janus Henderson (JHG) $8.0B are the closest pure-play active-manager comps; SEI Investments (SEIC) $11.0B, Jefferies (JEF) $10.8B, American Financial (AFG) $11.9B, Assurant (AIZ) $13.8B, Globe Life (GL) $14.0B round out the FMP list (several are insurers, less comparable). Against BEN and JHG, IVZ's re-accelerating organic growth and QQQ optionality are relative positives; its leverage is a relative negative.

9. Management, capital allocation & guidance

Capital allocation: disciplined and shareholder-friendly for a mature firm — dividend raised to $0.215/qtr (~3.1% yield), buybacks stepped up to $40M/1.6M shares in Q1'26, and $500M of senior notes redeemed at January 2026 maturity. De-levering + return of capital is the right playbook at this ROIC.
Insider activity: the only recent Form 4s in the sample are routine director equity awards (8,112 shares each, 2026-05-15) at $0 cost — normal comp, not open-market conviction buying or alarming selling. No signal either way.
Management's own guidance (half-weighted — they talk their book): Invesco's Q1'26 earnings release (SEC 8-K, filed 2026-04-28) does not give explicit numeric forward revenue/EPS guidance; instead CEO Andrew Schlossberg emphasizes the 11th consecutive quarter of positive organic growth ($22B net inflows), 14% net revenue growth, a 25% rise in adjusted operating income and 30% growth in adjusted diluted EPS, "meaningful operating leverage," and continued balance-sheet strengthening and capital return. Treat this as management's self-interested framing: directionally corroborated by the reported numbers, but not hard guidance. Formal forward guidance was not provided in the release.

10. Catalysts & what to watch

Next earnings: 2026-07-28 (Q2'26; Street EPS $0.61, revenue ~$1.26B). The key lines: net long-term flows (does the 11-quarter streak extend?) and adjusted operating margin (does operating leverage hold?).
QQQ economics: the full-quarter run-rate of management fees now that QQQ is an open-end ETF — the single biggest fundamental swing factor near-term.
AUM & markets: because revenue is AUM-linked, the market's own direction is a first-order catalyst/risk.
Flow mix: China JV, ETFs/Index, fixed income and private markets have been the inflow engines; QQQ and fundamental equities have leaked — watch whether the high-fee categories grow.
De-levering pace: further debt paydown / preferred management would improve the risk score.

Thesis tripwires (what would change the call): two consecutive quarters of net outflows; adjusted operating margin rolling back below ~31%; a market drawdown that shrinks AUM materially; or a dividend/buyback pullback signaling balance-sheet stress.

11. Key risks

Market-linked revenue (structural/cyclical): ~72% of revenue is AUM-based management fees; a market decline shrinks AUM and revenue with little management can do — amplified by beta 1.59.
Fee compression (secular): the entire active-management industry faces relentless fee pressure from passive giants; IVZ must run to stand still.
Leverage & preferred overhang: net debt $8.1B plus ~$2.5B preferred ahead of common; optically high leverage limits flexibility in a downturn even with strong FCF.
Concentration on QQQ: a large share of franchise value and recent flow narrative rides on one product tied to the Nasdaq-100 — a tech-heavy, volatile index.
No expert corroboration: Synthos has zero KB claims on IVZ, so there is no independent expert panel supporting (or challenging) the thesis — the call rests entirely on fundamentals and quant, and is sized/verdicted conservatively for that reason.

12. Verdict, position sizing & monitoring

Watch. Invesco is a legitimate, under-the-radar turnaround: 11 straight quarters of organic inflows, the QQQ open-end conversion adding real fee revenue, +300 bps of margin expansion, a raised dividend, stepped-up buybacks and active de-levering — all at ~9–10× forward adjusted earnings with a ~15% FCF yield. That's a respectable setup. But it is also a mature, high-beta, market-linked asset manager in a fee-compressing industry, our ~$31 base fair value sits essentially on the Street's $30 consensus (so no large edge), and there is no expert conviction in the Synthos KB to lean on. The honest label is Watch — own-it-if-you-like-value-and-income, but nothing here forces the trade.

Sizing: if entered, satellite value/income, ~1–3% — not a core or flagship weight. Better risk/reward on a pullback toward the 200-DMA (~$25.50) or on a proven extension of the flow streak.
Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $27.01.
Single biggest risk: AUM is market-linked and fees compress structurally — a market downturn hits revenue with no offsetting lever.

Provenance & disclosures

Traceability: 0 KB claims, breadth 0 — there is no expert coverage of IVZ in the Synthos knowledge base. This note is explicitly fundamentals- and quant-driven; no claim_ids are cited because none exist. Fabricated conviction is structurally impossible (claim-ID reconciliation), and we have not invented any.
Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03. Forward figures are analyst consensus (FMP), labeled as estimates; all per-share earnings referenced for valuation are adjusted (non-GAAP), because FY25 GAAP was distorted by a non-cash intangible impairment.
Management caveat: management's Q1'26 release commentary is management's own book, half-weighted by design; no explicit numeric guidance was provided.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").